Podcasts about mfn

Most Favored Nation (MFN) pricing has taken over conversations at conferences, client meetings, and boardrooms alike, but what does it actually mean in practice?In this episode, we continue the conversation on evolving US pricing policy. Host Louise Bennett is joined by three of the Access Infinity team: Leigh Ann Bruhn, Louisa Byrne, and Richard Mee. Together, they discuss the current MFN landscape from multiple angles: US payer and policy, global pricing and modelling, and ex-US strategic implications. From the ground at the recent ACCESS Forum in New Orleans, to conversations with European clients, the team explores where MFN stands today, what remains deeply uncertain, and how manufacturers are (and aren't) responding. A timely conversation for anyone navigating the intersection of US policy and global market access strategy.To connect and continue the conversation with Leigh Ann, Louisa and Richard, visit the LinkedIn links below: www.linkedin.com/in/leighannvalue/ www.linkedin.com/in/louisa-oliver-byrne-05a3b212b/ www.linkedin.com/in/richard-mee-3a227a11/ You can also let us know what you thought of this episode by emailing host Louise on louise@accessinfinity.com. To explore other useful resources on this topic, go to accessinfinity.com/news-resources. Send a text

Dit is aflevering 146 van Licht op Legal. In deze podcast gaat Marjolijn van Deventer, advocaat Arbeidsrecht en MfN-mediator bij Van Benthem & Keulen, in op de Wet toelating terbeschikkingstelling van arbeidskrachten (WTTA). De WTTA treedt per 1 januari 2027 in werking en brengt fundamentele veranderingen met zich mee voor de uitzend- en detacheringsmarkt.De WTTA zorgt ervoor dat de markt voor arbeidsbemiddeling transparanter en eerlijker wordt, en dat alleen betrouwbare uitleners personeel mogen aanbieden aan inleners.Organisaties mogen straks alleen nog personeel inlenen van uitleners met een officiële toelating (vergunning) om arbeidskrachten ter beschikking te mogen stellen.De WTTA heeft dan ook grote gevolgen voor zowel inleners als uitleners. Wat betekent dat in de praktijk? En hoe bereid je je hier als organisatie op voor? In deze aflevering van Licht op Legal vertelt Marjolijn hoe de WTTA in elkaar zit en waarom de wetgever heeft besloten dit nieuwe stelsel in te voeren.Vervolgens bespreekt Marjolijn voor wie de WTTA geldt, welke uitzonderingen er bestaan en hoe het nieuwe toelatingsstelsel precies werkt. Ook vertelt zij welke data relevant zijn en hoe een goede voorbereiding op de WTTA er uit ziet. Zij sluit de podcast af met praktische tips voor bedrijfsjuristen die te maken hebben met het in- of uitlenen van personeel. Wilt u meer informatie over dit onderwerp? Neem dan contact op met Marjolijn van Deventer.Heeft u suggesties voor een onderwerp of wilt u dat onze experts hun licht laten schijnen op uw juridische vraagstuk? Mail ons via lichtoplegal@vbk.nl. Licht op Legal kunt u via onze website, Spotify, Apple Podcasts of uw eigen favoriete podcastapp beluisteren.Dit is een podcast van Van Benthem & Keulen. U vindt ons op:vbk.nlLinkedInFacebookInstagram Hosted on Acast. See acast.com/privacy for more information.

I detta sportlovsavsnitt blir det en hel hög med lyssnarfrågor (50:00). Hänt sedan senast river Ola av (11:00), efter det en titt på Multiconsult (40:45) och en oväntad makrospaning på slutet. Välkomna! Kavaljer hittar ni på: www.kavaljer.seHoldings finns på: https://www.modularfinance.se/holdingsBörsdata finns på: www.Borsdata.sewww.MFN.se har stenkoll på bolagens kommunikation och viktiga datumLäs mer om Läkare utan gränsers verksamhet här: https://lakareutangranser.se/Nästa avsnitt släpps torsdagen den 26 mars. Hosted on Acast. See acast.com/privacy for more information.

Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury's analysts assess what the deal does for the Foster City, Calif.-based biotech's pipeline.The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week's PhRMA Forum, which focused on China and the Trump administration's most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA's about-face on the recent vaccine application from Moderna.View full story: https://www.biocentury.com/article/658516#BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA00:00 - Introduction02:34 - Gilead's Arcellx Buy11:14 - ctDNA Surrogate Endpoints21:59 - PhRMA Forum Takeaways29:19 - FDA Moderna U-turnTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Slowly but surely – and just in time for the State of the Union – the full picture of the Trump Administration's Most-Favoured Nations drug pricing policy is coming into focus. At the end of last year, CMS published the draft guidance for its GLOBE and GUARD pricing models, which establish MFN pricing in Medicare Part B and Part D, respectively. And earlier this month TrumpRx – the government's promised patient-facing discount portal – finally went live. On today's podcast, Jonah Comstock is joined by Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert, to break down what we know and what we still don't know about each of these developments. Among other things, Valder Curran breaks down how the two CMS pilot programmes will work, what statutory authority CMS is leaning on (and whether that authority is likely to be challenged), and how the industry is responding. Comstock and Valder Curran also discuss TrumpRx and how impactful it's shaping up to be, at least based on what's been revealed so far. And how do those negotiated MFN deals fit in to all this? We can't give you the answers to all your questions about MFN – too much is still up in the air. But this podcast will at least give you an idea of what those open questions are and how they're likely to play out. You can listen to episode 246 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Host: Cindy Allen Published: February 20, 2026 Length: ~18 minutes Presented by: Global Training Center Summary “Tariff Friday” may go down as one of the most pivotal days in recent trade history. In this episode of Simply Trade: Cindy's Version, Cindy Allen breaks down the U.S. Supreme Court's 6–3 decision ruling that IEEPA does not authorize the President to impose tariffs. The Court found that the authority to levy taxes and tariffs belongs to Congress, and that the term “regulate” under IEEPA does not include the power to raise revenue. Inspired by Taylor Swift's Opalite, Cindy walks through what the ruling actually says, what it does not say, and what importers and customs brokers should do right now while awaiting further instruction from the Court of International Trade (CIT) and CBP. The decision may have brought sunlight—but operational clarity will take time. This Week in Trade (Before the Ruling) • Awaiting details on Taiwan 15% MFN (or higher) structure • Pending clarification on India IEEPA reciprocal adjustment (25% to 18%) • Indonesia agreement announced with 19% tariff and textile tariff-rate quota • No movement on elimination of First Sale • No further action on ending IEEPA on Canada • U.S. manufacturing indicators down; stock market up The Supreme Court Decision The Supreme Court issued a 6–3 opinion finding that IEEPA does not grant authority to impose tariffs. Key findings: • IEEPA contains nine enumerated action verbs — none include taxing or raising revenue • Congress alone holds the constitutional authority to levy tariffs • Specific delegated authorities (Sections 301, 232, 122, 338) include limitations and procedural controls • Because Congress created these specific tariff authorities, a broad IEEPA tariff authority cannot be implied • During peacetime, the President does not have independent tariff authority The Court remanded the case back to the lower court — likely the U.S. Court of International Trade (CIT) — which must now issue implementation instructions. What We Still Don't Know • When the CIT will issue instructions • When (or if) CBP will suspend IEEPA tariff collection • Whether refunds will be automatic or require action • Whether de minimis is affected • Whether related trade agreements tied to IEEPA remain intact • Whether the administration pivots to Section 122 or 338 authorities What Importers Should Do Right Now Cindy's recommendation is clear: Continue paying duties until formal CBP guidance is issued. Why? • Duties were in effect at time of entry • Monthly statement entries could otherwise be considered unpaid • CBP systems still contain IEEPA tariff numbers and edit checks • Programming updates will take time Stopping payment prematurely could create compliance risk. Refunds, when issued, will likely require formal action — potentially protests, post-summary corrections, or other ACE updates. Given the volume of entries involved, automatic refunds appear unlikely. Key Takeaways • IEEPA tariffs have been ruled unlawful for revenue purposes • Congress retains sole tariff authority • Operational changes will depend on CIT and CBP implementation • Continue paying duties until official guidance is issued • Refund mechanics remain unclear • Trade professionals must remain disciplined and patient Resources & Mentions • Global Training Center • TradeForce Multiplier • U.S. Supreme Court Opinion (24-1287) Credits Host: • Cindy Allen – LinkedIn • TradeForce Multiplier Producer: • Lalo Solorzano – LinkedIn Subscribe & Follow New episodes every Friday. Presented by Global Training Center — providing education, consulting, workshops, and compliance resources for trade professionals. • Simply Trade Podcast on LinkedIn • Global Training Center on LinkedIn • YouTube • Spotify • Apple Podcasts • Trade Geeks Community

Arunima Sinha, from the U.S. and Global Economics team, discusses how an upcoming Supreme Court decision could reshape consumer prices, retail margins and the inflation outlook in 2026.Read more insights from Morgan Stanley.----- Transcript -----Arunima Sinha: Welcome to Thoughts on the Market. I'm Arunima Sinha from Morgan Stanley's U.S. and Global Economics Teams.Today: How a single Supreme Court ruling could change the tariff math for U.S. consumers.It's Friday, February 13th at 10am in New York.The U.S. Supreme Court is deciding whether the U.S. president has legal authority to impose sweeping tariffs under IEEPA. That decision could come as soon as next Friday. IEEPA, or the International Emergency Economic Powers Act, is the legal backbone for a significant share of today's consumer goods tariffs. If the Supreme Court limits how it can be used, tariffs on many everyday items could fall quickly – affecting prices on the shelf, margins for retailers, and the broader inflation outlook.As of now, effective tariff rates on consumer goods are running about 15 percent, and that's based on late 2025 November data. And that's quite a bit higher than the roughly 10 percent average, which we're seeing as tariffs on all goods. In a post IEEPA scenario, we think that the effective tariff rate on consumer goods could fall to the mid-11 percent range.It's not zero, but it is meaningfully lower.An important caveat is that this is not going to be eliminating all tariffs. Other trade tools – like Section 232s, which are the national security tariffs, Section 301s, the tariffs that are related to unfair trade practices – would remain in place. Autos and metals, for example, are largely outside the IEEPA discussion.The main pressure point we think is consumer goods. IEEPA has been used for two major sets of tariffs. The fentanyl-related tariffs on Mexico, Canada, and China, and the so-called reciprocal tariffs applied broadly across trading partners. And these often stack on top of the existing tariffs, such as the MFN, the Most Favored Nation rates, and the section 301 duties on China that were already existing before 2025.The exposure is really concentrated in certain categories of consumer goods. So, for example, in apparel and footwear, about 60 percent of the applied tariffs are IEEPA related. For furniture and home improvement, it's over 70 percent. For toys, games, and sporting equipment, it's more than 90 percent. So, if the IEEPA authority is curtailed, the category level effects would be meaningful.There are caveats, of course. The court's decision may not be all or nothing. And policymakers could turn to alternative authorities. One example is Section 122, which allows across the board tariffs for up to 15 percent for 150 days. So, tariffs could just reappear under different tools. But in the near term, fully replacing IEEPA-based tariffs on consumer goods may not be straightforward, especially given ongoing affordability concerns.So, how does that matter for the real economy? There are two key channels, prices and margins. On prices we estimate that about 60 percent of the tariff costs are typically passed on to the consumers over two to three quarters, but it's not instant. Margins though could respond faster. If companies get cost relief before they adjust prices downwards, that creates a temporary margin tailwind. That could influence hiring, investment and earnings across retail and consumer supply chains.Over time, lower tariffs could also reinforce that broader return to core goods disinflation starting in the second quarter of this year. And because tariff driven inflation has weighed more heavily on the middle- and lower-income households, any eventual price relief could disproportionately benefit those groups.At the end of the day, this isn't just a legal story. It is a timing story. If IEEPA authority is curtailed, the arithmetic shifts pretty quickly. Margins move first, prices follow later, and the path back to goods disinflation could accelerate. That's why this is one ruling worth watching before the gavel drops.Thanks for listening. If you enjoy the show, please leave us a review wherever you listen and share thoughts on the market with a friend or colleague today.

Host: Cindy Allen Show: Simply Trade – Cindy's Version Published: February 13, 2026 Length: ~15 minutes Presented by: Global Training Center State of Grace: Tariffs, First Sale Under Fire, and a Glimmer of Stability In this episode of Cindy's Version, Cindy Allen, CEO of TradeForce Multiplier, walks through another busy week in global trade and ties it to Taylor Swift's “State of Grace”—focusing on the idea that, despite the shock of recent policy shifts, this is still a “worthwhile fight” for trade professionals. From new trade deals to challenges against tariff policy and first sale threats, Cindy explains what's changing and where there are signs of hope.​ What You'll Learn in This Episode New trade deals and tariff shifts A U.S.–Taiwan deal capping total tariffs at 15% (either limiting MFN above 15% or applying 15% where MFN is lower). Details emerging on agreements with Guatemala, El Salvador, Argentina, and an India deal rolling back some reciprocal tariffs tied to India's Russian oil purchases.​ Where to find official text and specifics: USTR's website.​ Border infrastructure and electronic bonds The administration's threat to block the opening of the long‑planned Gordie Howe Bridge between Detroit and Ontario over funding/ownership disputes, and why Canada and Michigan intend to proceed regardless. How this new public crossing will compete with the privately owned Ambassador Bridge for billions in daily cross‑border trade.​ CBP's move to mandate electronic surety bond filing for all bonds, formalizing what many brokers, importers, and sureties already do—and why Cindy strongly supports it.​ Section 232 guidance softens (slightly) New CBP guidance on 232 tariffs for steel, aluminum, and copper, dialing back earlier aggressive interpretations. Trade groups have received written clarification allowing certain labor/overhead costs to be prorated into steel/aluminum values instead of fully loaded, even as petitioners continue to argue that none of those costs should be included. Why importers should review the latest guidance carefully, track affected entries, and monitor the ongoing Court of International Trade challenge.​ USMCA and IEPA signals from Capitol Hill Senate Finance Committee signaling support for extending USMCA, seeking stability before any renegotiation, while the administration is rumored to prefer separate bilateral deals with Canada and Mexico.​ The House vote to end IEPA duties on Canada for certain non‑USMCA goods—a positive step toward predictability, though the bill still must clear the Senate and avoid a presidential veto.​ First sale under threat Introduction of a bill to eliminate first sale, driven by some of the same groups that pushed to curtail de minimis and oppose duty‑reducing mechanisms generally. Why this is significant: many large importers rely on first sale, provide extensive upstream data to CBP, and enable deeper supply‑chain visibility and risk management. Trade associations have already begun weighing in to defend first sale; Cindy flags this as a fight to watch closely.​ EU deal conditions and a big auto bill The EU moving its U.S. tariff deal through lawmakers but adding elements like sunset deadlines and “security triggers” that go beyond earlier negotiating language.​ Ford announcing an expected 900 million dollar 232‑related tariff hit after previously anticipated automotive offsets were disallowed for several months—raising questions about how other automakers will fare and whether Ford might push back through protests or litigation.​ Global trade up, U.S. trade down Conference insights from Manifest: global trade volumes are rising overall, but trade into the U.S. is declining, as exporters pivot to other markets they perceive as less costly and less complex. This trend aligns with a surge in trade deals worldwide that do not include the U.S.​ Why “State of Grace”? Cindy connects the week's developments to Taylor Swift's “State of Grace,” highlighting the line: “I never saw you coming and I'll never be the same. This is a state of grace, this is a worthwhile fight.” She uses this to frame: How studies now confirm what many suspected—U.S. consumers have already paid roughly 1,000 dollars more due to tariffs, with an additional 1,300 dollars expected in the coming year. How tariffs are hitting companies and rural communities: constrained exports for U.S. agriculture, rising small‑farm bankruptcies, and knock‑on impacts to local economies. Research showing that about 90% of tariff costs are passed from suppliers to U.S. importers, then to consumers, and even to manufacturers who never import directly but rely on tariff‑burdened inputs.​ Despite this, she sees reasons for cautious optimism: Companies challenging IEPA and 232 in court. Large players like Ford publicly quantifying tariff impacts. Congress beginning to reassert its constitutional role over tariffs and question security‑based justifications used as broad economic tools. Early, coordinated pushback against eliminating first sale—stronger than what was seen around de minimis.​ For Cindy, these developments suggest the industry may be entering a state of grace—a moment where data, legal challenges, and coordinated advocacy start to rebalance the conversation and make the fight for smarter trade policy worth it.​ Credits Host: Cindy Allen Producer: Annik Sobing Presented by: Global Training Center Sponsor: PAX AI ​ Listen & Subscribe Simply Trade main page: https://simplytrade.podbean.com​ Apple Podcasts: https://podcasts.apple.com/us/podcast/simply-trade/id1640329690​ Spotify: https://open.spotify.com/show/09m199JO6fuNumbcrHTkGq​ Amazon Music: https://music.amazon.com/podcasts/8de7d7fa-38e0-41b2-bad3-b8a3c5dc4cda/simply-trade​ Connect with Simply Trade Podcast page: https://www.globaltrainingcenter.com/simply-trade-podcast​ LinkedIn: https://www.linkedin.com/showcase/simply-trade-podcast​ YouTube: https://www.youtube.com/@SimplyTradePod​ Join the Trade Geeks Community Trade Geeks (by Global Training Center): https://globaltrainingcenter.com/trade-geeks/

While only about 13% of the nation's population is Black, the percentage of incarcerated Blacks can be as high as 50 %. The proportion of Black men on death row is significantly higher than that of whites.Our guest, Courtney Teasley, a criminal defense lawyer, emphasizes the responsibility that defense attorneys have in contributing to incarceration rates. Some lawyers fail to communicate with clients, push plea deals without proper consultation, and neglect to use available court resources or file necessary motions.This lack of diligence can result in missed opportunities for discovering evidence that could change the outcome of a trial. Courtney stresses that defense lawyers should fight for their clients and not simply “go along to get along,” especially in smaller counties where maintaining good relationships with judges is common practice.Courtney described the DAMM community—Disproportionately Affected Marginalized Minority—as the primary demographic impacted by incarceration. Systemic factors such as inadequate education in financial literacy, criminal justice literacy, and civics contribute to this problem. Many individuals are not taught their rights or how to hold government officials accountable, nor are they given the tools to pursue financial stability beyond low-wage jobs.These gaps leave people vulnerable to crimes of poverty and ill-equipped to navigate the legal system if accused. Having financial means, legal knowledge, and civic understanding provides leverage and empowerment, but these advantages are often unavailable in marginalized communities.Courtney's initiatives focus on legal literacy, financial literacy, and civics. She teaches these subjects through mock trial programs at high-priority schools and at HBCUs, aiming to address the lack of foundational legal knowledge. Her business, MFN, stands for Mindset, Finesse, and Non-Negotiable Boundaries, and is dedicated to advocacy training and lawyer coaching.Courtney also discussed the school-to-prison pipeline, which refers to the disproportionate punishment of Black students in schools, which leads to higher rates of suspension and disciplinary actions that can lead to the juvenile justice system.She advocates for empowering students through education in legal literacy, civics, and financial skills, noting that access to such knowledge and opportunities is often limited. Programs and curricula she develops aim to bridge these gaps and provide students with tools for legal and financial empowerment.Ultimately, the need for competent, passionate lawyers in criminal defense is critical. The goal is not necessarily to achieve acquittals for all clients, but to ensure the state proves its case and to minimize negative impacts on individuals' records and communities. Creative solutions, rehabilitation, and strategic partnerships are encouraged to address root causes of crime and support long-term positive outcomes.

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Tim Scott, President & CEO of Biocom California, a biopharma executive with more than two decades of experience, including spinning out companies from UC San Diego and leading firms acquired by BioMarin and Novartis, to discuss how California’s life sciences ecosystem became a global innovation engine, why the state’s research and venture networks matter, and how policy headwinds such as the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) reference pricing reshape investment, rare disease development, and competition with Europe and China. Key Topics: Biocom Origins: Municipal policy roots, industry advocacy, ecosystem evolution across California. Innovation Network: University and research density, regional clusters, talent, and collaboration effects. Capital Pathway: NIH and NSF support, SBIR and STTR bridges, venture appetite, and liquidity. MFN and IRA: Pill penalty incentives, orphan exemption stakes, Medicare exposure, and VC pullback. Next-Gen Development: AI-enabled discovery, faster trial enrollment, digital twins, and regulator openness. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

On this week's episode, Josh Schimmer, Sam Fazeli, Brian Skorney, and Yaron Werber kick off with a discussion on policy with special guest BIO's CEO John Crowley, overviewing what it means for the U.S. to “win” the biotech race against China, emphasizing the need for innovation and ensuring access to medicines. The conversation shifts to the latest at the FDA, where John acknowledges concerns around consistency at the agency and expresses optimism following conversations with FDA leadership at the JP Morgan Healthcare conference earlier this month. Next, the co-hosts discuss major investments in China, including AstraZeneca's $15B commitment to China through 2030, focusing on R&D, manufacturing, and partnerships. Shifting back to U.S. policy, the group addresses the growing measles outbreak, highlighting the belief that science, data, and policy pressure will win out over anti-science rhetoric. Next, John notes that codifying MFN would be devastating for the industry. The conversation turns to deals, with Merck's decision not to acquire Revolution Medicines, noting that the company's current strong cash position and recent deals will likely make them attractive to Big Pharma in the future. Next, Eikon Therapeutics' planned $273.5M IPO is also highlighted. The episode concludes with an overview of the FDA's clinical hold on a Regenxbio gene therapy and discussion on Amgen stepping away from its OX40 partnership. *This episode aired on January 30, 2026.

Detta avsnitt består till största del av en genomgång av samtliga 36 bolag som finns kvar i våra sju B&H-portföljer. Innan detta lite hänt sedan sist (8:30). Bolagen: AQ Group (46:00); Bahnhof (50:13); BTS (53:35); Fenix Outdoor (56:20); Nederman (60:27); Proact IT (63:15); Systemair (66:45); Enea (70:00); Nilörn (73:50); Ogunsen (78:55); Formpipe (82:45); Know IT (85:40); Careium (92:15); VBG (96:36); Björn Borg (100:30); Fagerhult (104:28); Inwido (106:55); Kabe (109:18); New Wave (112:20); Note (115:20); Svedbergs (117:40); Ework (122:20); Scanfil (127:10); Softronic (129:37); Beijer Alma (134:27); Bergman&Beving (135:41); Betsson (137:45); Brdr AOJ (140:24); Byggmax (143:30); Elanders (145:07); G5 (148:25); Harvia (151:37); Thule (153:53); Bravida (157:08); Kitron (160:34); Tomra (163:20). Mycket nöje!Kavaljer hittar ni på: www.kavaljer.seHoldings finns på: https://www.modularfinance.se/holdingsBörsdata finns på: www.Borsdata.sewww.MFN.se har stenkoll på bolagens kommunikation och viktiga datumLäs mer om Läkare utan gränsers verksamhet här: https://lakareutangranser.se/Nästa avsnitt släpps torsdagen den 26 februari. Hosted on Acast. See acast.com/privacy for more information.

Kia ora,Welcome to Tuesday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.Today we lead with news repricing for American risk is underway, evidenced by rising UST yields, a falling US dollar, and commodity price spikes.First up today, American durable goods orders rose in November by more than expected to be +10.5% higher than year ago levels, a gain that has impressed markets, and came as a complete surprise. Non-defense capital goods orders, excluding aircraft, were up +4.3%, also a good gain.But there are a number of factors we should take into account when assessing this data. It is 'nominal' and not inflation adjusted and tariff-taxes will be a part of the increase. Second, we looked back at the ISM and S&P Global factory PMIs for November and they did not pick up this type of gain. The ISM one actually reported contraction, the S&P Global and unchanged expansion. And then there is the 'new management' at the US data agency that releases this data. All three factors mean we should wait a bit to see if this is an outlier result. Risks abound.Meanwhile, the Chicago Fed's National Activity Index came in below trend in November, although not as negative as it was in October. This is the ninth below-trend reading in the past twelve months.It was a similar story for the Dallas Fed factory survey, which also recorded a pullback, for January, although not as steeply as it did in December. Output and new orders rose, but the overall index was held back by a sharp jump in prices paid for inputs. Only about half that was recovered by prices received even though that rose sharply too.There was a US Treasury bond auction today and while it was well supported, it did bring a notable rise in the yield achieved. The 2 year bond delivered a yield of 3.55% at todays event, up from 3.45% at the prior equivalent event a month ago. This is the largest shift in yields we have observed at these events in more than a year. The US's ballooning deficit can't really afford rising interest rates, but then again it couldn't afford the tax cuts for the rich either.Singapore's industrial production dipped rather sharply in December to end up +8.3% from the same month a year ago. But the December pullback was less than observers had expected.In addition to Auckland, and Australia, Monday was also a public holiday in India, Republic day. And the two top EU officials were in New Delhi to seal a key trade deal between the two economic powers. In fact, it has been called "the mother of all deals" and is set to be signed later today. Both sides are making major concessions to get it done and it is likely to boost trade in a globally significant way. The EU will get major access to India's car market. India will get the EU's preferential tariff MFN treatment.The UST 10yr yield is now just on 4.21%, down -3 bps from this time yesterday.The price of gold will start today at US$5087/oz, up +US$104 from yesterday and a new record again. Silver is up proportionately more, up +US$12/oz at US$115/oz and also a record high. Platinum has risen to US$2857/oz, up +US$116/oz.Tin prices are up +9.5% today, and copper is up +1.5%. Both build on recent surges to record highs. A falling greenback accentuates these rises, but all commodities are still priced in USD.American oil prices are holding at yesterday's at just under US$61/bbl, while the international Brent price is firmish, now just under US$65.50/bbl and down -50 USc.The Kiwi dollar is up +30 bps from yesterday, now at 59.7 USc. Against the Aussie we are up +10 bps at 86.4 AUc. Against the euro we are also up +10 bps at just on 50.4 euro cents. That all means our TWI-5 starts today just under 63.5, and up +40 bps from yesterday, its highest since late September.The bitcoin price starts today at US$87,677 and down just -0.3% from this time yesterday. Volatility over the past 24 hours has been modest at just under +/- 1.4%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston and we'll do this again tomorrow.

 In Episode 123 of DC EKG, Joe Grogan sits down with Jackson Hammond (Senior Policy Analyst, Paragon Health Institute) to unpack what the latest CMS National Health Expenditure (NHE) data says about where U.S. health care is headed. They break down the June 2025 NHE release, compare it to Jackson's earlier “Paragon Prognosis” analysis, and explain what changed, what didn't, and what it means for affordability, Medicare, Medicaid, and long-run fiscal pressure. They also connect the spending outlook to Jackson's paper, “How to Reform the CMS Innovation Center with a Choice and Competition Approach,” and debate whether CMMI is bending the cost curve or just adding bureaucracy without accountability. Jackson argues we should aim for health care so affordable you barely need insurance. Chapters / Timestamps  00:00 – Intro + welcome  00:55 – Jackson's background: how he got into health policy  03:39 – Focus areas: Medicare, hospitals, drug pricing, PBMs, 340B  05:14 – What the NHE report is showing  06:14 – $5.2T → $5.6T → $8.6T: why the trajectory matters  08:00 – Why health spending isn't really “optional”  10:11 – Where the money is going: payer mix + per-enrollee costs  12:23 – Medicaid costs, provider taxes, and state financing tactics  15:58 – Medicare spending pressure and fiscal risk  21:06 – Misconception: “coverage = care”  26:18 – Why provider payments keep rising (post-COVID demand + consolidation)  33:01 – Rural care, consolidation, and the REH / hub-and-spoke model  40:08 – Drug pricing: retrospective vs prospective MFN  49:20 – 2026 outlook + closing thanks In This Conversation  • NHE 2025: what the June 2025 data confirms about spending growth and the federal share.  • Rising prices, flat health: why prices climb while outcomes lag.  • Medicare and Medicaid: why they remain major budget drivers.  • Coverage vs access: why an insurance card doesn't guarantee care or better health.  • Hospitals and consolidation: what's driving higher payments and fewer choices.  • Rural vs urban: why patients bypass local hospitals and what a better model could look like.  • Drug pricing: what MFN approaches might mean for costs and innovation.  • 2026: what Jackson expects next and what reform could realistically look like. Key Takeaways  • NHE data points to continued, unsustainable spending growth.  • Medicare and Medicaid drive long-term budget pressure.  • Consolidation and payment incentives shape prices as much as utilization.  • CMMI reform hinges on accountability, choice, and competition.  • Smarter drug pricing policy should lower costs without undermining innovation. About Our Guest  Jackson Hammond is a Senior Policy Analyst at the Paragon Health Institute focused on health spending, CMS policy, and reforms centered on choice, competition, and patient-centered care. He authors Paragon's “Paragon Prognosis” analyses and wrote “How to Reform the CMS Innovation Center with a Choice and Competition Approach.”

Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This Week podcast, BioCentury's analysts discuss Senior Biopharma Analyst Danielle Golovin's four-part analysis of how next-generation targeting chimeras (TACs) are evolving. The analysts assess the $2.2 billion takeout of Rapt Therapeutics by GSK, which gave the pharma an allergy asset that the biotech sourced in China in 2024, and movement in Washington on priority review vouchers, NIH's budget and the White House's “most favored nation” drug pricing policy. The analysts also discuss takeaways from their meetings on the sidelines of the J.P. Morgan Healthcare Conference.View full story: https://www.biocentury.com/article/658112#InducedProximity #TargetingChimeras #BiotechMA #DrugPricingPolicy #JPMHealthcare00:00 - Introduction 03:17 - JPM Highlights09:17 - GSK's Acquisition of RAPT14:46 - Next-Generation Targeting Chimeras21:41 - MFN and Pediatric PRVsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this episode, journalist and author Puja Mehra speaks with trade policy expert Ajay Srivastava, founder of the Global Trade Research Initiative (GTRI), about the impact of steep US tariffs on India's exports and what the latest data reveals about the state of India–US trade negotiations. Drawing on sector-wise export trends, Srivastava explains the puzzling two-step trajectory in India's exports to the US—a sharp initial fall followed by a partial recovery even as tariffs climbed to 50%—and outlines why this resilience may be driven by temporary adjustments.He also examines whether India can realistically diversify away from the US market, why such shifts are slow and constrained by India's export basket, and how global competition—particularly from China—limits alternative options. The conversation also touches on India's recent spurt of free trade agreements, arguing that they reflect a revival of stalled negotiations rather than a fundamental shift in trade strategy. The discussion highlights why the India–US talks go far beyond a conventional trade agreement, touching on agriculture, domestic policy autonomy, and strategic concerns that India has consistently treated as red lines. Tune in for insights on what the trade data signals about India's negotiating space, the costs of prolonged uncertainty, and the limits of compromise in a high-stakes economic relationship.(00:00) Setting the India–US trade context(00:42) Sharp export decline and partial rebound(02:44) Why exports revived despite higher tariffs(03:06) How exporters are sharing tariff losses(05:33) Why the recovery may not last(06:44) Is export diversification really happening(09:27) Why tariffs won't speed negotiations(10:12) Trade deal versus strategic demands(12:34) Employment risks from prolonged tariffs(13:13) India's non-negotiable red lines(14:21) What India can realistically offer(15:57) Country-specific versus MFN concessions(16:45) Are India's FTAs a strategy shift(18:35) Why FTAs are being fast-tracked(19:16) Using data to read trade signalsFor more of our coverage check out ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠thecore.in⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe to our Newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow us on:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on Most Favored Nation (MFN) drug pricing and its knock-on effects for jobs, state budgets, and the generic supply chain. Over the past year, proposals to link U.S. prices to those in other countries have collided with inflation pressures, tariff debates, and reshoring efforts, creating new uncertainty for manufacturers, payers, and policymakers. In an environment where expectations about future returns are shifting, and the rules of the game are still being defined, this episode is designed as a year-end guide to what MFN-style policies could mean in practice and how to think about the tradeoffs. Throughout 2025, we our research on MFN-style reference pricing with a series of podcast episodes where host Duane Schulthess sat down with leaders across the generic, distribution, and policy landscape. In this highlights episode, we revisit several of those conversations: Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks Patrick Kelly: Inside the Generic Supply Chain Squeeze John Murphy: Generics, Biosimilars, and U.S. Policy VT’s Grumpies (Harry Bowen, Joe Hammang) Talk MFN Key Topics: MFN Mechanics Explained: How tying U.S. prices to the lowest GDP-adjusted price in a reference basket translates into steep cuts for top-spend medicines in Medicare Parts B and D and shapes expectations across commercial and Medicaid contracts. Jobs, Earnings, & State Budgets: What our modeling suggests about potential impacts on employment, earnings, and tax revenue under MFN-style reference pricing, and how those effects concentrate in R&D-intensive regions and manufacturing hubs. Spillovers Into Medicaid, 340B, & ASP: Why MFN in Medicare does not stay in Medicare, how Medicaid best price and 340B ceilings pull discounts across programs, and what lower ASP add-ons could mean for hospital and community oncology margins. Generics, Shortages, & Tariffs: How razor-thin margins for sterile injectables and generic manufacturers interact with purchaser consolidation, tariff shocks, and price referencing, raising the risk of exits, inventory write-downs, and persistent shortages. Global Competition & Offshoring: How aggressive reference pricing can accelerate shifts in trials, licensing, and high-value manufacturing to countries that offer more predictable returns, and what that implies for long-run U.S. competitiveness. Alternatives To MFN: Ideas from our guests on value-based approaches, targeted incentives, and other tools that can improve affordability without hollowing out domestic capacity, innovation, and resilience in the generic and biosimilar supply chain. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

I detta avsnitt blir det en intervju med Lindabs VD, Ola Ringdahl (121:50). Hänt sedan senast river vi av (28:26), övriga bolag är: Securitas (06:00), Proact (68:35), Alligo (89:20), och slutligen Inwido (104:25). Välkomna! Kavaljer hittar ni på: www.kavaljer.seHoldings finns på: https://www.modularfinance.se/holdingsBörsdata finns på: www.Borsdata.sewww.MFN.se har stenkoll på bolagens kommunikation och viktiga datumLäs mer om Läkare utan gränsers verksamhet här: https://lakareutangranser.se/Nästa avsnitt släpps torsdagen den 29 januari. Hosted on Acast. See acast.com/privacy for more information.

Crypto funding rounds often look glamorous from the outside: big name investors, big valuations, big narratives. But behind the scenes, the terms can look very different — and sometimes, radically so. In this episode of Bits + Bips, host Steve Ehrlich sits down with reporter Jack Kubinec, who broke the story about Berachain's Series B and one of the most unusual terms we've seen in a major token deal: a lead investor receiving the right to ask for its entire $25 million investment back, for up to a year after Berachain's token launched. Jack walks through what the documents show, why lawyers say the clause is extremely rare, and how a refund right like this could impact other investors, and even trigger MFN clauses. They also unpack Berachain's market struggles since TGE, the state of the Nova Digital fund inside Brevan Howard, and the transparency questions this episode raises across crypto venture investing. Read the full story here on Unchained Thank you to our sponsor Uniswap!  Host: Steve Ehrlich, Executive Editor at Unchained Guest: Jack Kubinec, Crypto Journalist and Podcast Host Timestamps: 0:00 — Start 0:25 — Steve introduces Jack 2:24 — What the documents reveal 5:17 — Why Brevan Howard's refund is a big problem 9:21 — How refund clauses really work 14:09 — Jack's interactions with the Bera team and how Smokey responded to the story 19:29 — Why the MFN clause is key 26:19 — How Breva Howard Digital didn't actually invest in Bera 30:18 — What investors should learn from a deal like this Learn more about your ad choices. Visit megaphone.fm/adchoices

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

Audio roundup of selected biopharma industry content from Scrip over the business week ended November 1, 2025. In this episode: Pfizer's unwavering pursuit of Metsera; Lilly's obesity momentum; Merck & Co.'s MFN negotiations; Novartis's promising Sjögren's results; and the rising Chinese pressure on US innovation. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-2K33BM6BLBDU7JH7QMETUXUKPE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to just 1-2 months. As part of the Trump administration's push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA's entry into the drug pricing fray. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott and counsel Monica Groat explore the voucher awards in detail and discuss how the accelerated review period might affect launch strategies, whether companies with no voucher will be disadvantaged, and potential risks and concerns. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

尊敬的李在明总统， Your Excellency President Lee Jae-myung, 各位同事： Colleagues, 很高兴来到韩国历史文化名城庆州，同大家共谋亚太发展大计。感谢李在明总统和韩国政府的周到安排。 It is my great pleasure to be here in Gyeongju, a city of rich history and culture, to join you in discussing the future of the Asia-Pacific. Let me begin by thanking President Lee Jae-myung and the ROK government for the thoughtful arrangement. 亚太经合组织成立30多年来，从勾画亚太自由贸易区蓝图到推动建设亚太共同体，引领亚太地区走在全球开放发展前列，助力亚太成为全球经济最具活力的地区。 Over the past 30-plus years since its founding, from drafting the blueprint of the Free Trade Area of the Asia-Pacific (FTAAP) to advancing the vision of an Asia-Pacific community, APEC has been spearheading the region's rise to the forefront of global open development, and has made the Asia-Pacific the most dynamic part of the global economy. 当前，世界百年变局加速演进，国际形势变乱交织，亚太地区发展面临的不稳定不确定因素增多。越是风高浪急，越要同舟共济。我们要坚守亚太经合组织促进经济增长、增进人民福祉的初衷，坚持在开放发展中分享机遇、实现共赢，推进普惠包容的经济全球化，构建亚太共同体。为此，我提5点建议。 Currently, changes unseen in a century are accelerating across the world. The international situation is fluid and turbulent. The Asia-Pacific faces growing uncertainties and destabilizing factors in its development. The rougher the seas, the more we must pull together. We should stay true to APEC's founding mission to promote economic growth and improve people's lives, and champion open development where everyone shares opportunities and emerges a winner. We should promote a universally beneficial and inclusive economic globalization, and build an Asia-Pacific community. To this end, I wish to make five proposals. 一是共同维护多边贸易体制。践行真正的多边主义，提高以世界贸易组织为核心的多边贸易体制的权威性和有效性。坚持世界贸易组织改革的正确方向，维护最惠国待遇、非歧视等基本原则，推动国际经贸规则与时俱进，更好保障发展中国家正当权益。 First, we should work together to safeguard the multilateral trading system. We must practice true multilateralism, and enhance the authority and effectiveness of the multilateral trading system with the WTO at its core. We should stick to the right direction of WTO reform, uphold the most-favored-nation (MFN), nondiscrimination and other fundamental principles, and update international economic and trade rules to reflect the changing times, so as to better protect the legitimate rights and interests of developing countries. 二是共同营造开放型区域经济环境。持续推进贸易和投资自由化便利化，深化财金领域合作，稳步推进区域经济一体化进程。把握《区域全面经济伙伴关系协定》高质量实施和《全面与进步跨太平洋伙伴关系协定》扩员契机，推动彼此对接、融合共进，为亚太自由贸易区建设聚势汇能。 Second, we should work together to build an open economic environment in the region. We should keep promoting trade and investment liberalization and facilitation, deepen fiscal and financial cooperation, and steadily push for regional economic integration. With the RCEP being implemented to high standards and the CPTPP membership expanding, we should help the two align with each other and progress together so as to inject impetus into the development of the FTAAP. 三是共同维护产业链供应链稳定畅通。坚持“拉手”而不是“松手”、“延链”而不是“断链”，积极寻找更多利益契合点，支持供应链开放发展。以《亚太经合组织互联互通蓝图》实施10周年为契机，不断做实做细硬联通、软联通、心联通，进一步夯实亚太地区开放发展基础。 Third, we should work together to keep industrial and supply chains stable and smooth. We must join hands rather than part ways, and strengthen our links rather than sever them. We should vigorously expand our common interests, and support the open development of supply chains. The tenth anniversary of the APEC Connectivity Blueprint gives us a good opportunity to strive for concrete and tangible results in physical, institutional and people-to-people connectivity so as to further consolidate the foundations for open development in our region. 四是共同推进贸易数字化绿色化。充分发挥数字技术对跨境贸易的促进作用，推进无纸贸易、智慧海关等务实合作。破除各种绿色壁垒，拓展绿色产业、清洁能源和绿色矿产合作。中方在亚太经合组织首倡设立的亚太示范电子口岸网络、绿色供应链网络，已经成为区域贸易数字化绿色化合作的重要平台。 Fourth, we should work together to advance the digital and green transformation of trade. We should make digital technologies a strong catalyst for cross-border trade, and promote practical cooperation in paperless trade, smart customs and other areas. We must remove various green barriers, and expand cooperation in green industries, clean energy and green minerals. The Asia-Pacific Model E-port Network and the Cooperation Network on Green Supply Chain initiated by China under APEC have become important platforms for regional cooperation on the digital and green upgrades for trade. 五是共同促进普惠包容发展。坚持以人民为中心的发展理念，着力解决发展不平衡问题，推动经济全球化更加包容、更可持续，更好惠及地区全体人民。中方同各方合作推进高质量共建“一带一路”，支持更多发展中国家实现现代化，为全球发展开辟新空间。中国已给予同我国建交的最不发达国家100%税目产品零关税待遇，愿通过商签共同发展经济伙伴关系协定落实对非洲建交国实施100%税目产品零关税措施，致力于同各国共同发展、共享繁荣。 Fifth, we should work together to promote universally beneficial and inclusive development. We should adhere to the people-centered development philosophy, focus on imbalances in development, and foster an economic globalization that is more inclusive, sustainable, and beneficial to all peoples in the region. China is working with various parties to promote the high-quality development of the Belt and Road Initiative, and supports the modernization drive of more developing countries, which will help open up new space for global development. We have given zero-tariff treatment on 100 percent tariff lines from the least developed countries having diplomatic relations with China, and stand ready to extend the same treatment to all African countries having diplomatic relations with China through the signing of agreements on economic partnership for shared development. We will continue to strive for common development and shared prosperity with all nations. 各位同事！ Colleagues, 中国始终坚持对外开放的基本国策，以实际行动推动建设开放型世界经济。过去5年，中国货物和服务贸易规模位居全球第一和第二，累计吸引外资逾7000亿美元，对外投资年均增速超过5%。中国的外资准入负面清单持续缩减，单方面免签持续扩容，自主开放和单边开放有序扩大，22个自贸试验区主动对接国际高标准经贸规则。中国对外开放的大门不会关闭，只会越开越大。 China always pursues the basic state policy of opening up, and has taken real steps to promote an open world economy. Over the past five years, China has ranked as the world's largest trader in goods and the second largest in services. It has attracted more than 700 billion US dollars in foreign investment in total, and its outbound investment has been increasing by over five percent on annual average. We have been shortening the negative list for foreign investment, and applying the unilateral visa-free policy to more countries. We are steadily expanding voluntary and unilateral opening up, and have actively aligned with high-standard international economic and trade rules through our 22 pilot free trade zones. China's door to the world will not close; it will only open wider and wider. 不久前，中共二十届四中全会通过了关于制定“十五五”规划的建议。中方将以此为契机，进一步全面深化改革，坚定不移扩大高水平对外开放，不断以中国式现代化新成就为亚太和世界提供新机遇。 A few days ago, the Recommendations for Formulating the 15th Five-Year Plan were adopted at the fourth plenary session of the 20th Central Committee of the Communist Party of China. We will take this opportunity to further deepen reform comprehensively and expand high-standard opening up, and create new opportunities for the Asia-Pacific and the world through the latest achievements of Chinese modernization. 谢谢大家！ Thank you.

Arthur Wong examines AbbVie (ABBV) following the healthcare company's earnings beat in its 3Q. He discusses the pharmaceutical pipeline, its oncology segment and current offerings like its autoimmune medication Humira. Arthur discusses the relationship between weaker consumer sentiment and patients willingness to spend on expensive medical treatments. He also talks about the industry trend to negotiate lower drug-costs with the Trump administration. He says tariffs and "MFN" Pricing (Most Favored Nation) are the biggest headwinds for pharmaceutical companies.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

In this episode, Audrey sits down with registered dietitian and founder of Nourished by Taylor, Taylor Lechner, to talk about what really happens when you've been on birth control for 10+ years and decide you're done. They get into why so many women lose their period, come off the pill, and suddenly have acne, anxiety, mood swings, gut issues, or no ovulation — and why it's not just “your hormones being crazy.” Taylor breaks down post–birth control syndrome, the labs she runs (HTMA, gut, minerals, thyroid), how copper and mineral depletion play into PMS and anxiety, and why testing > guessing. If you're thinking about coming off the pill/implant/IUD — whether or not you want to get pregnant — this is the one to listen to.Connect with Taylor:Taylor has a free gift for you all!!! :  Breakup with Birth Control MasterclassIG: nourishedbytayWebsite: https://nourished-by-taylor.com/Taylor Lechner, MFN, RD, LD, is a Registered Dietitian and founder of Nourished by Taylor. She helps women transition off birth control, heal acne, mood swings, and achieve symptom-free cycles with a root-cause approach. Her mission is to help women feel understood, empowered, and no longer dismissed with “that's just part of being a woman."  ✨✨ RISE Tribe - Next Steps✨✨Join us for RISE: The Happiness Summit - for free! - https://www.helloaudreyrose.com/risehappy 11:11 Sound Bath - www.helloaudreyrose.com/1111FREE 7 day Nervous System Reset Group - get daily nervous system reset practices in just 10 min a day, with Audrey as your guide https://www.helloaudreyrose.com/7days Nervous System Reset Training (Free): www.helloaudreyrose.com/reset RISE Sisterhood (private membership for nervous system regulation + spiritual alignment) www.helloaudreyrose.com/sisterhood 

Our U.S. Biotech and Biopharma analysts Sean Laaman and Terence Flynn discuss the latest developments that could be positioning the healthcare sector for strong outperformance.Read more insights from Morgan Stanley.----- Transcript -----Sean Laaman: Welcome to Thoughts on the Market. I'm Sean Laaman, Morgan Stanley's U.S. Small and Mid-Cap Biotech Analyst. Terence Flynn: And I'm Terence Flynn, Morgan Stanley's U.S. Biopharma Analyst. Sean Laaman: Today, we'll discuss how a rally in the healthcare sector is being driven by more favorable macro conditions. It's Tuesday, October 28th at 10am in New York. So, Terence, healthcare has lagged the broader market year-to-date, and valuations have been near historical lows. But recent weeks show strengthening performance. Policy headwinds have been front and center.What's changed in the regulatory environment and how is the biopharma sector adapting to these pricing and tariff dynamics? Terence Flynn: Sean, as you know, with many other sectors, tariffs were initially a focus earlier this year. But a number of companies in our space have subsequently announced significant U.S. manufacturing investments to reshore supply chains. And hence, the market's less focused on tariffs in our space right now. But the other policy dynamic and focus is what's called Most Favored Nation or MFN drug pricing. Now, this is where the President's been focused on aligning U.S. drug prices with those in other developed countries. And recently we've seen several companies announce agreements with the administration along these lines, which importantly has provided investors with more visibility here. And we're watching to see if additional agreements get announced. Sean Laaman: Got it. Another hurdle for Large-cap biopharma is a looming expiration of patents with [$]177 billion exposed by 2030. How is this shaping M&A trends and strategic priorities? Terence Flynn: For sure. I mean, as you know, Sean, patent expiry is our normal part of the life cycle of drug development. Every company goes through this at some point, but this does put the focus on company's internal pipelines to continue to progress while also being able to access external innovation via M&A. Recently we have started to see a pickup in deal activity, which could bode well for performance in SMID-cap biotech. Sean Laaman: At the same time, you believe relative valuations look compelling for Large-cap biopharma. Where are valuations versus where they've been historically? What's driving this and how should investors think about positioning? Terence Flynn: Absolutely. Look, on a price to earnings multiple, the sector's trading at about a 30 percent discount to the S&P 500 right now. Now that's in line with prior periods of policy uncertainty. But as policy visibility improves, we expect the focus will shift back to fundamentals. Now, positioning to me still feels light here, given some of the patent cliff dynamics we just discussed. Now, Sean, with the Fed moving toward rate cuts, how do you see this impacting your sector on the biotech side? Sean Laaman: Well, Terence, particularly in my space, which is Small- and Mid-cap biotech companies, they're typically capital consumers are not capital producers. They're particularly sensitive to the current rate environment.Therefore, they're sensitive to spending on pipeline. They're sensitive to M&A. So, as rates come down, we expect more spending on pipeline and more M&A activity, which is generally positive for the sector. Looking forward, biotech sector is generally the best performing sector on a six-to-12-month timeframe post the first rate cut. Terence Flynn: Great. You've also talked about this SMID to Big thesis on the biotech side. Can you explain what's driving that? Sean Laaman: Sure Terence. There's three pieces to the SMID to Big thematic. So, we in SMID-cap biotech, we cover 80 to 90 companies. About a third of those are newly, kind of profitable companies. Those companies are turning from being capital consumers to capital producers. We see about $15 billion of cash on balance sheets for 2025, going to north of 130 billion by 2030. That's the first piece. The second piece is due to regulatory uncertainty at the USFDA. We're seeing more attractive valuations amongst clinical stage names. That's the second piece. And third piece relates to your coverage, Terence. I refer back to that [$]177 billion of LOE. So, we expect generally that M&A activity will be quite high amongst our sector. Terence Flynn: And let's not forget about AI, which has implications across the healthcare space. How much is this changing the dynamic in biotech, Sean? Sean Laaman: It is changing, but we're really at the beginning. I think there's three things to think about. The first one is faster trial recruitment. The second one is faster regulatory submissions. And the third one, which is the most interesting, but we're really at the beginning of, is faster time to appropriately targeted molecules. Terence Flynn: Great. And maybe lastly, what are the key risks and catalysts for SMID-cap biotech in the current environment? Sean Laaman: As always, we're focused on pipeline failures in terms of risk. Secondly, in terms of risk, we're looking at regulatory risk at the FDA. And thirdly, we're looking at the rise in China biotech and the competitive dynamic there.Whether you're watching large cap biopharma, M&A moves, or the rise of cash-rich, SMID-cap biotechs, the healthcare sector setup is unlike anything we've seen in years.Terence, thanks for speaking with me. Terence Flynn: Always a pleasure to be on the show. Thanks for having me, Sean. Sean Laaman: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with two Vital Transformation colleagues to explore key trends in drug pricing and macroeconomic policy: Joe Hammang: US Business Director at Vital Transformation. Harry Bowen: Consulting Economist at Vital Transformation. They unpack the Trump administration’s “Most Favored Nation” approach as applied to Medicaid, contrast it with past Medicare proposals, and discuss modeled employment, tax, and GDP impacts. The conversation explores why effects would differ by company and therapy area, the EU’s move toward streamlined compulsory licensing, the knock-on risks for premiums and investment, the fragility of the generics market, and how global competition - including China’s growing clinical footprint - could reshape innovation incentives. Key Topics: MFN Basics: What is MFN?, Medicaid focus versus Medicare, price-leveling concept. Modeled Impacts: Jobs and GDP effects, tax revenue losses, insurance premium pressure. Uneven Company Effects: Medicaid-heavy portfolios, orphan and rare disease exposure, negotiation dynamics. EU Signals: Compulsory licensing push, UK pricing realities, risks of spillover to U.S. policy. Innovation and Competition: Biologics cost structure, generic market fragility, and China’s rising clinical pipeline. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

In this episode, Greg and Rob chat about what the government shutdown might mean for 340B Program oversight in the short-term. They'll also discuss a flurry of developments from manufacturers recently. Specifically, they'll highlight efforts to promote more direct-to-consumer (DTC) pathways for obtaining medications, all related to a recent Trump Administration executive order calling for “most favored nation (MFN)” pricing for drugs in the U.S. SpendMend will be at the 340B Grantee Conference in Atlanta October 20 – 22.  Stop by our booth and also catch our presentation at the “Ask the Experts – Open Forum” while you are there!

Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Josh Sigurdson reports on the news of Donald Trump's $70 billion deal with Pfizer as part of his MFN agenda to lower drug prices. While in theory, this causes Pfizer to lower costs, one should also remember that Pfizer is already raising costs following production by thousands of times. It's like a store offering 50% off after raising their prices 200%. It's a scam. Moreover, it encourages people to be more dependent on pharmaceutical drugs, putting more pills in the hands of Americans. Wasn't this administration all about fighting back against Big Pharma? So far, Trump still claims the mRNA covid vaccines saved millions of lives, new mRNA vaccines have been issued to children ages 6 months to 11 years old, the FDA is fast tracking Self Amplifying RNA for Bird Flu without safety tests, they're green lighting fake salmon for mass production, RFK Jr who was confirmed by a pharma funded house is pushing MMR Measles vaccines, he's also calling for all Americans to wear "wearable devices" to track their health at all times and get them more pharmaceutical pills and Trump has openly said he wants an Operation Warpspeed 2.0 as he meets with Bill Gates. Where exactly is this justice Big Pharma was supposed to face? In fact, Pfizer CEO Albert Bourla has said time and time again that he works great with RFK Jr. This $70 billion payout for Pfizer ensures that they will be immunized from tariffs and scrutiny and will force the US government into a long-term dependency on its products, essentially ensuring future first dibs on pharma mandates and simultaneously allowing Albert Bourla to evade any future indictments. So, the US taxpayers is paying murderous Big Pharma who knowingly targeted children with injections it knew would cause heart illness and cancer. 70 billion dollars. All to become a bigger monopoly and not face justice. How do we win with this? How do you win? You don't. Stay tuned for more from WAM! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025

Genmab closed out a busy third quarter for M&A in biopharma, picking up cancer biotech Merus for $8 billion. This deal—the year's fifth largest—came just a week after Pfizer acquired rising obesity star Metsera for $4.9 billion. Just seven days later, Metsera made the New York–based pharma look like a genius with mid-stage data for one of the deal's centerpiece therapies, MET-097i, showing 14% placebo-adjusted weight loss over 28 weeks.After months of tarrying and threats, President Donald Trump announced last week that 100% tariffs would take effect Oct. 1—with broad exceptions for companies that have taken steps to build out their domestic manufacturing footprints. One company that has answered that call—as well as a letter sent by the president to 17 of the largest pharma companies requesting action on his most-favored-nation drug pricing policy—is Pfizer. In a joint oval office announcement with Pfizer CEO Albert Bourla and HHS officials, Trump said Pfizer would offer all new medicines at MFN prices.Meanwhile, over at the FDA, CDER Director George Tidmarsh, who has flown relatively under the radar since taking the post in July, took to LinkedIn to address the subject of relying on surrogate endpoints in drug approvals. In a since deleted post, Tidmarsh called out Aurinia Pharmaceuticals' lupus drug as an “egregious” example of this phenomenon. CDER's sister agency, CBER, also made a splash last week, publishing three draft recommendations intended to accelerate the development of cell and gene therapies.Speaking of CGT, maybe the biggest clinical development news of the year emerged from this space last week when uniQure announced that its gene therapy for Huntington's disease, AMT-130, slowed disease progression by 75% after three years. With these data in hand, uniQure plans to file for FDA approval of the treatment in the first quarter of 2026. If successful, AMT-130 would be the first genetic therapy for the intractable neurodegenerative disease.Finally, biopharma's glass ceiling just got a little more tightly sealed. Emma Walmsley, the industry's first female CEO, is stepping down after nine years at GSK, handing the reins to current chief commercial officer, Luke Miels. When Walmsley officially departs on Dec. 31, she will leave Vertex CEO Reshma Kewalramani and incoming Takeda CEO Julie Kim to represent the sisterhood at the highest ranks of the biopharma industry.

In this episode, former CMS official Jon Blum reflects on the evolution and impact of the IRA's drug provisions—from foundational drivers and political trade-offs to how 2026 Part D redesign and the M3P cost-smoothing program are reshaping access. We explore why M3P adoption remains limited, how CMS is monitoring plan behavior around negotiated pricing, and what shrinking standalone Part D options may mean for patients, especially in rural areas. Jon also challenges the “blame game” in Washington—emphasizing the systemic incentives behind each actor—and shares his own prescription for equitably balancing drug affordability, innovation, and policy integrity, including thoughts on MFN and future reform paths.

On this episode of The AIE Podcast... The great migration is under way And, we have a mini raid wrap up! Congradullances to Stask! Kdf Recruits incoming And, we are catching up with ourselves All that and more coming up right now... Podcast Audio Raw Video http://youtu.be/BfHzOgkipbI Open Welcome to episode #438 of the podcast celebrating you, the Alea Iacta Est gaming community, the die has been podcast. This is Mkallah: To my left is Tetsemi: - (catch phrase here). And to my right is Mewkow: (catch phrase here). This week we are having a host show Welcome, friends! Ok, we'll be digging into what we have been up to in and out of game shortly, but first, let's cover this week's news... AIE News Community Mandatory Fun Nights Where the fun is mandatory but the attendance is not. Sunday - Destiny 2 8:30 pm Eastern Monday - GW2 9:30 pm Eastern Monday - STO 10:00 pm Eastern Tuesday - SWTOR 9:00 pm Eastern Wednesday - HFO Mythic+ Mayhem (WoW) 8:00 pm Eastern Friday - ESO 9:00 pm Eastern Saturday - LotRO 8:30 pm Eastern Saturday - FFXIV (Maps) 9:30 pm Eastern Saturday - Noob Raid (WoW) 11:00 pm Eastern Streaming and Guild Podcast News We have a ton of AIE member podcasts! Want to know where to find them? Look no further than here- New Overlords Podcast (Max and Sema) https://www.newoverlords.com Boards and Swords (Chris and Philip) https://boardsandswords.com/blog?category=Boards%20%26%20Swords Dr. Gameology ( Dr. Daniel Kaufmann ) https://drgameology.com/ STO - Fleet Action Report (Grebog and Nikodas) https://www.youtube.com/@fleetactionreport A Podcast Reborn: A FFXIV Community Podcast (Brandon aka Old Man Franks, Meagan, and Rho) - NSFL https://www.bonusroll.gg/directory/a-podcast-reborn/ WoW The great migration to the active 5 horde co-guilds is going well. Member removal of accounts that haven't logged in for a year or more also was completed and we have plenty of room for growth, so we kept the two recruiting co-guilds, Libertas and Fortuna, open for another month. The consolidation on the alliance side and culling of accounts also left us with plenty of room for growth. It feels so much better to login and see so many others in guild playing. We encourage those who haven't made the migration to please do so, and don't be shy. If you need help, officers are here for you. We get it, it can be scary to hit the /gquit, but I think you will like rejoining an active co-guild. Alliance side MFN raid team HFO is 7/8 on normal and working on the dance with Demensius. Noob Raid ran Firelands for the Timewalking quest, with thanks to Ashayo for getting a skip on the (again) bugged Lord Rhyolith. Ragnaros was troublesome but we took him down eventually, then hopped over to the new Raid, Manaforge Omega to defeat first boss, Plexis Sentinel on Normal. Kiddie Aggro has feasted upon Nexus King Saladbar and are now 7/8 Heroic in Manaforge Omega. Next stop: Dimensius. Surely our bestie Xal-Atath will reward us well for his demise this time? Raid Team Dungeoneering INC has advanced to 4/8 Heroic with successful kills of Loomithar, Soulbinder and Forgeweaver. Raid team So Let's Go Skating got 3/8 heroic last week with a sub 1% best pull on Araz, they're going back in this evening for revenge! SWTOR AIE in swtor has a new Guild Master! Corley has passed the reigns on to Stask. Show them both some love! ‘Where's the Cantina' Operations Team is hosting a 16 man run of Terror From Beyond on Monday, September 8. For fun times and a Galactic Seasons objective, check in discord for more info and to let Machete know you are interested. There are no gear requirements, but you must be 80 and subbed FFXIV New relic step is out Cosmic Exploration has been updated with a new map to visit, and new rewards to craft and gather for. Map night continues every Saturday at 9:30 pm eastern. Don't be intimidated,

What if your gym could be the first line of defense against chronic disease? In this insightful episode of the Fitness Business Podcast, host Justin 'JT' Tamsett discusses the concept of 'Exercise is Medicine' with expert Lisa Dougherty, who has 27+ years of experience in the field. They explore the significant impact of physical inactivity on global health and the economy, emphasizing the crucial role of tailored exercise in combating chronic diseases. Lisa shares her journey and the evolution of specialized fitness training for various medical conditions. They also discuss best practices for gyms and trainers, the importance of advanced education, and how gyms can build respect within the healthcare continuum. The episode finishes with details on Lisa's upcoming virtual global medical fitness conference, bringing together a wealth of knowledge and expertise for fitness professionals worldwide.  Key highlights from the episode: - A global health wake-up call: Why inactivity is projected to cost $314–$446 billion annually by 2050 and how gyms can position themselves as part of the healthcare solution. - Best practices for “exercise as medicine” programs: Education requirements, record-keeping, safety protocols, and emotional intelligence as core skills. - Business opportunities in medical fitness: How specializing in chronic condition populations can set you apart from competitors and create long-term client loyalty.   Know the SECRET codeword? Submit it here for the chance to win a $100 Amazon Gift Card!* https://www.fitnessbusinesspodcast.com/codeword    Ready for more: - Become an FBP Insider and get 7 days FREE to start! Learn more on Patreon: https://patreon.com/FitnessBusinessPodcast - Our FREE LIVE online events created specifically for fitness business owners, managers, and coaches who want to sharpen their skills and grow their business - Learn More: https://fitnessbusinesspodcast.com/onlineevents - Leave us a voicemail: https://fitnessbusinesspodcast.com/leave-us-a-voicemail/ - Leave a rating on Spotify or Apple Podcasts: https://fitnessbusinesspodcast.com/review/ Quotes: “It is crucial for fitness and allied healthcare professionals working with the aging population to have this higher level of knowledge, skill, and expertise.” - Lisa Dougherty “I started the MFN to improve the quality of life of the many millions of people with chronic disease and medical conditions.” - Lisa Dougherty “The fitness industry still targets the' nearly fit'. Which is, you know, 15% of the population, and those are the shark infested waters. And 85% of the rest of the population has obesity, diabetes, high blood pressure, cardiovascular disease, osteoporosis, cancer…it's a scroll of diseases.” - Lisa Dougherty Resources: - Become an FBP Insider on Patreon: https://patreon.com/FitnessBusinessPodcast - Fitness Business Podcast's LinkedIn Community: https://www.linkedin.com/groups/9878228/ - Mystery Shopping for Fitness Businesses: https://mysteryshoppingforfitnessbusinesses.com.au/    Our Guest: Lisa Dougherty, Medical Fitness Expert Website: https://www.MedFitFoundation.Org LinkedIn: https://www.linkedin.com/in/lisadougherty1/    Event: 2025 Virtual Global Medical Fitness Conference: https://www.fbasucceed.com/medfit Use the Code: FITBIZ to save 25% (case sensitive!)   Sponsor's Pitch: Clint Aragona Max Members AI Website: https://www.maxmembers.ai/Email:clint@maxmembers.ai LinkedIn: https://www.linkedin.com/in/clinten-aragona-470123290/ and https://www.linkedin.com/company/maxmembers   Merch Sponsor: ROGUE - https://www.roguefitness.com/ Be a Merch Sponsor - https://fitnessbusinesspodcast.com/merch/   REX Roundtables: Website: www.REXRoundtables.comEmail: Eddie@REXRoundtables.com   Free Online Live Events: https://fitnessbusinesspodcast.com/onlineevents   REX Roundtables Trusted Suppliers: 1. Reinig Insurance: Ken Insurance Guy specializes in risk management and insurance for fitness businesses https://theinsuranceguy.com/ Power Plate: Whole-body vibration for fitness and wellness - https://powerplate.com/ ROR Partners: offering data-driven marketing strategies to enhance customer relationships. https://rorpartners.com/ HR Network: All your HR needs solved at the end of the phone. https://hrnetworkinc.com/ Referrizer: Automates marketing and referrals for your business https://business.referrizer.com/   About Our Guest: Lisa Dougherty has been in the medical fitness space for over 25 years. She founded the MedFit Network in 2013, which serves as both a professional membership organization and a free online resource directory. She established the MedFit Education Foundation, a nonprofit organization, in 2017 to elevate the quality and quantity of available education for fitness and allied healthcare through educational webinars, online courses, and virtual conferences. Lisa has been recognized as a fitness leader on multiple occasions, including by Personal Fitness Professional Magazine and The Huffington Post. The White House acknowledged her as a “Champion of Change”. About Your Host: Justin "JT" Tamsett is a fitness industry veteran with over 30 years of experience who aims to reduce global healthcare costs by promoting physical activity. Through his company Active Management, he provides business coaching to fitness entrepreneurs, leads 8 REX Roundtables in the US and Australia, and has spoken at over 40 conferences across 23 countries. His ultimate goal is to create a world of opportunity for his daughter Zoe by helping more people move and stay healthy, while empowering gym owners to build successful businesses that contribute to a healthier society   Please note: We only recommend products we care about (affiliate links support our free content). Thank you for your support!

Kirsten Axelsen is an economist specializing in Medicare reimbursement, payer negotiations, and innovative reimbursement contracts. She’s a fellow of the Aspen Institute and a visiting scholar with the American Enterprise Institute. She joins host Duane Schulthess to unpack bipartisan pressure on drug prices, the Part D redesign’s rapid shift of catastrophic costs to plans, and the resulting premium versus coverage tradeoffs and PDP exits. Axelson explains why forecasting IRA impacts is uncertain, how nine versus thirteen-year timelines tilt incentives toward biologics, and why price controls can weaken both generic entry and biosimilar uptake. The discussion explores MFN-style ideas and trade uncertainties, vertical integration around biosimilars, and practical fixes from EPIC-like timelines to building a faster, more connected U.S. clinical-trial ecosystem with better participant support. Politics & Incentives: Trump MFN attempts, bipartisan pressure on high drug prices, and insurer dynamics versus the pace of biomedical innovation. Part D Redesign: The rapid shift of catastrophic costs to plans, premium versus coverage tradeoffs, PDP exits, and access challenges in rural areas. Modeling & Consequences: Limits of CBO forecasts, uncertainty bands, design choices around price controls, and risks to post-market and follow-on research. Competition Levers: Small molecule disincentives, low biosimilar uptake on formularies, generic entry pressures under price controls, and plan behavior. Policy Paths: EPIC-style timeline fixes, negotiation mechanics, MFN and trade uncertainties, and making U.S. clinical trials faster, more connected, and participant-friendly. Recorded on July 28, 2025. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 22, 2025. In this episode: Madrigal regains MASH lead with EU Rezdiffra approval; Viking's obesity data scare investors; China assets lead GLP-1 deals; CSL and others restructure; and Indegene exec on DTP and MFN policies. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T77LV22VANAL5GNPCC2YUVLZBE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Click On Picture To See Larger Picture The EU folded and they made a deal with the US. The US has the advantage now. Trump admin is putting pressure on Fed Gov Cook to resign. Trump is positioning himself to have the majority in the Fed to vote for a rate cut. The tariffs will begin paying off the debt. Trump is now dismantling the 5th column. We are in the process of taking back the country from the evil tyrants. The [DS] might try a [FF] before the midterms. If they believe they don't have a chance in winning there is a possibility of an event. Trump and the patriot's are expecting this to happen and this is why the NG is being put into place to counter the riots and other events.   Economy https://twitter.com/howardlutnick/status/1958484249406775348 This deal: Eliminates EU tariffs on all U.S. industrial goods, Creates historic access to the vast European markets for American farmers, fishermen and ranchers, Delivers $750B in European energy demand during President Trumps term And EU firms will invest an additional $600B in new investments in America The America First Trade Agenda has secured the most important trading partner creating a major win for American workers, U.S. industries, and our national security. Tariffs should be one of America's favorite words. See the full Joint Statement below (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");   https://twitter.com/KobeissiLetter/status/1958486074885586971   only MFN tariffs on EU aircraft/parts, generics, chemical precursors, and scarce natural resources 4. EU to eliminate tariffs on all US industrial goods and grant preferential access for US seafood/agriculture Energy & Tech Purchases: 1. EU to buy $750B in US LNG, oil, and nuclear products 2. EU to purchase at least $40B in US AI chips Investment & Cooperation: 1. EU firms to invest $600B in US strategic sectors by 2028 2. Both sides to negotiate rules of origin to ensure benefits remain bilateral 3. Exploring cooperation on steel and aluminum market protections 4. Joint commitment to tackle digital trade barriers; EU pledges not to adopt network usage fees 5. Considering measures for secure supply chains, including tariff-rate quota solutions https://twitter.com/HedgieMarkets/status/1958245475704041673   the Fed is using inflation as a gauge for rate cuts, then rate cuts are nowhere near. Core CPI inflation is back above 3.0% and PPI inflation just jumped +0.9% MoM, its biggest jump in 3+ years. That said, the last Fed meeting happened BEFORE the last jobs report. Regardless, today's Fed Minutes were a major blow to the “Fed pivot” camp. Powell appears ready to hold rates steady if he feels it is necessary. The September jobs report will decide everything. https://twitter.com/pulte/status/1958281801023033751 Hypothetically, if she were to step down (or resign) from her position, the President would nominate a replacement to fill the vacancy for the remainder of her unexpired 14-year term. That nominee would then require confirmation by the U.S. Senate before taking office, as outlined in the Federal Reserve Act. This is the standard process for filling vacancies on the seven-member Federal Reserve Board. There are currently six members on the Federal Reserve Board of Governors,

Rabi's Showdown! Rabindra Dhant's Mindset Before & After | Coach Diwiz Strategy Revealed. Nepal's MMA pride first bantamweight champion Rabindra Dhant returns after his epic MFN fight, sharing untold stories from fight night, pre-fight mindset, training strategies, and post-fight fame. Joined by Coach Diwiz, this powerful podcast dives deep into fight analysis, mental toughness, injury concerns, ruthless 5x5 training, and what's next in their MMA journey. From surviving a dangerous choke, handling media without playing the victim, to inspiring the next generation of Nepali fighters, this conversation is raw, honest, and inspiring.Enjoy candid moments on trash talks, handling fame and media, and the powerful “It's Rabi's show” declaration. Rabindra opens up about his family life and rejecting victim mindsets, while Coach Diwiz sends a strong message to mainstream media about respecting fighters' journeys. With highlights from the MFN fight night and discussions on Nepal's unique fighting genes on the MFN fight cards, this podcast offers fans an unfiltered look at the realities of professional fighting. Perfect for fight enthusiasts and those interested in mixed martial arts, training strategies, and the mental and physical demands of competitive fighting. GET CONNECTED WITH Diwiz Piya Lama: https://www.instagram.com/diwizpiyalama/ Rabindra Dhant: Instagram: https://www.instagram.com/rabindra_dhant1/  

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 8, 2025. In this episode: Trump ups pressure on MFN pricing; Pfizer says pharma working with Trump on direct sales; Sanofi says direct sales worth considering: Aurigene Oncology CEO on biotech valuations and more; and Novartis progresses pipeline-in-a-product assets. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RCXSH2B5EVCC3IIK35GXUSNZVA/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored Nation drug pricing reforms in the U.S., analysts and industry watchers are questioning how far the president’s authority extends, while several drugmakers have signaled a willingness to negotiate. In this week’s episode of "The Top Line," we break down the latest Most Favored Nation pricing pressures in the U.S., how companies are responding and which facets of the proposal might fall short of Trump’s goals. Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss the current state of those reform efforts and past attempts to rein in U.S. drug costs, followed by a brief discussion on tariffs. To learn more about the topics in this episode: Pfizer CEO touts 'extremely productive' talks with Trump administration as MFN pricing, tariff threats close in White House threatens to 'deploy every tool in our arsenal' to implement most-favored-nation drug pricing All branded drugs not facing generic, biosimilar competition must abide by MFN order in 'all markets,' HHS tells pharma Trump ups the ante on pharma tariffs, saying they will reach 250% See omnystudio.com/listener for privacy information.

Chinese biotech is the lone bright spot for the biopharma financial markets in 1H25, as macro concerns about the most favored nation (MFN) pricing policy and FDA weigh on the prospects for biotech elsewhere. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the positives — and negatives — impacting investor sentiment headed into the second half of the year. The team also discuss where the quantum computing revolution could have its biggest impact on drug development, and review the proposals and accomplishments of FDA Commissioner Marty Makary over his first 100 days in office.View full story: https://www.biocentury.com/article/#biotech #biopharma #pharma #lifescience #financialmarkets #FDA #quantumcomputingReach us by sending a text

On this episode of The AIE Podcast... We have your Summer of Love schedule With D&D, and Lore, and Remembrance Day, and more Congrats to the SWTOR on a total galactic win Big Changes are coming to LOTRO And, we are chatting amongst ourselves All that and more coming up right now... Podcast Audio Raw Video http://youtu.be/sm6TJ3q-Mj4 Open Welcome to episode #436 of the podcast celebrating you, the Alea Iacta Est gaming community, the die has been podcast. This is Mewkow: To my left is Mkallah: - (Hey, folks, there are fig and goat cheese pinwheels in the guild kitchen). And to my right is Tetsemi: (catch phrase here). This week we have your Summer of Love schedule and other gaming news! Ok, we'll be chatting about what we've been up to shortly, but first, let's cover this week's news... AIE News Community Where the fun is mandatory but the attendance is not. Sunday - Destiny 2 8:30 pm Eastern Monday - GW2 9:30 pm Eastern Monday - STO 10:00 pm Eastern Tuesday - SWTOR 9:00 pm Eastern Wednesday - HFO Mythic+ Mayhem (WoW) 8:00 pm Eastern Thursday- Board Game Night (1st and 3rd Thursdays) 7:00 pm Eastern/6:00 pm Central Friday - ESO 9:00 pm Eastern Saturday - LotRO 8:30 pm Eastern Saturday - FFXIV (Maps) 9:30 pm Eastern Saturday - Noob Raid (WoW) 11:00 pm Eastern Streaming and Guild Podcast News We have a ton of AIE member podcasts! Want to know where to find them? Look no further than here- New Overlords Podcast (Max and Sema) https://www.newoverlords.com Working Class Nerds (Marcus and Nick) - NSFL https://workingclassnerdscom.wordpress.com Boards and Swords (Chris and Philip) https://boardsandswords.com/blog?category=Boards%20%26%20Swords Dr. Gameology ( Dr. Daniel Kaufmann ) https://drgameology.com/ STO - Fleet Action Report (Grebog and Nikodas) https://www.youtube.com/@fleetactionreport A Podcast Reborn: A FFXIV Community Podcast (Brandon aka Old Man Franks, Meagan, and Rho) - NSFL https://www.bonusroll.gg/directory/a-podcast-reborn/ Summer of Love July 26th - August 2nd with August 2nd being Remembrance Day So far Summer of Love will include two D&D one-shots, one hosted by Duskmire in a Star Wars setting and the other hosted by Kraemer for ESO on their MFN night. If anyone is interested in hosting a One-Shot, contact Gustytail. We'll also have Lore Night, where participants will share a story from in game lore, events or their character's backstory. In WoW, we'll have trivia night in Guild chat with pet and transmog giveaways, WoW Hide and Seek, and a Delves event. SWTOR The big news in SWTOR is that we won both our Total Galactic War last week and are using this week to pick prizes, lie on beaches with pina coladas, and not do uprisings for a bit. It was a close race on some days, but we pulled away near the end and our competition just could not catch us. Check out discord for our victory screenshot. And while you are there, feel free to click on the capybara link. It will make your day better. ESO Summer of Love we have the D&D one shot down at the docks going on on our usual MFN Friday August 1st and we will meet at Kini's main house on Saturday August 2nd for Remembrance Day in the Chapel room. FFXIV Come join us for map night at 9:30 eastern every Saturday! As long as you have completed the Heavensward main story there's stuff for you to do! You can even join us as part of the free trial, or if you're in a different FC or world! We're on Goblin in the crystal data center. STO Fleet Action Report, your weekly dive into the world of Star Trek Online! In Episode 257, join hosts Nikodas, Tabbytha, and Grebog as they plunge into the unknown—deep into Fluidic Space itself! This week, they tackle the eerie missions “Assimilation” and “Fluid Dynamics”, where the Borg and Undine collide in one of STO's most unsettling story arcs. What happens when the Borg find a way to assimilate the Undine?

Current developments, such as most favored nation (MFN) pricing, grabbed much of the spotlight when key industry stakeholders met in Philadelphia for the Pricing and Contracting USA Conference. In this episode of Connected With Latham, Allan Thoen, Director & Associate General Counsel with Sandoz, joins Washington, D.C. partner Chris Schott and associate Danny Machado to discuss impressions and takeaways from the conference. And read our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

Audio roundup of selected biopharma industry content from Scrip over the business week ended 13 June 2025. In this episode: breaking down big pharma's executive pay; US vaccine panel upheaval; Merck's RSV approval; MFN and Japan; and the future of Pfizer and Arvinas's partnership. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-BC44NPMNMNGMXP5X4STR4ZAFU4/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Tune in as Glenn Hunzinger, PwC's Health Industries Leader, and Phil Scalfani, PwC's Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration's executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader drug supply chain, and share perspectives on how organizations can navigate the uncertainty ahead.  Discussion Highlights: The MFN executive order is a bold attempt to lower U.S. drug prices by benchmarking them against the lowest prices paid in other high-income countriesPharma companies may be forced to rethink global pricing strategies, balancing U.S. price cuts with potential increases or market exits abroadA proposed shift to direct-to-consumer drug access could disrupt traditional roles for pharmacies, distributors, and pharmacy benefit managers (PBMs)Companies are preparing for significant uncertainty by reassessing deals, modeling financial impacts, and closely monitoring upcoming rulemaking and potential legal developmentsSpeakers:Glenn Hunzinger, Health Industries Leader, PwCPhilip Sclafani, Partner, Pharma & Life Sciences, PwCLinked materials:Most Favored Nation prescription drug pricing Executive OrderFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Market Update: Resurgent AI, Market Movements, and Crypto Insights In this episode of Dividend Cafe, Brian Szytel from West Palm Beach discusses recent market trends on a quiet trading day. The S&P 500 saw modest gains, while the Dow was down slightly. Key points include an uptick in AI sector activity driven by policy shifts and supply chain dynamics, significant M&A activity in the utility sector, and a cautious perspective on pharmaceutical pricing changes due to the MFN executive order. Brian also addresses an audience question about cryptocurrency investments, advising on its volatility and practicality in portfolios. Looking ahead, he previews an action-packed economic calendar for the following day. 00:00 Introduction and Market Overview 01:06 AI Sector Resurgence and Policy Shifts 02:10 Utility Sector and Power Generation 02:58 Trade Policies and Sector Impacts 03:29 Pharmaceutical Industry Disruptions 05:27 Upcoming Economic Data and Events 06:02 Cryptocurrency Investment Considerations 08:15 Conclusion and Sign Off Links mentioned in this episode: DividendCafe.com TheBahnsenGroup.com

President Trump's executive order signed on May 12, 2025, aims to reduce U.S. prescription drug prices by aligning them with the lowest prices paid internationally through a "most favored nation" (MFN) policy. However, several aspects of the order may allow pharmaceutical companies to circumvent its intended effects. It is the best attempt yet by any sitting President to reign in Big Pharma. The order is intended to force Big Pharma to charge Americans the same price they charge in nations where it is the least expensive. The problem is there are some "loopholes" and ambiguity in the order. I believe those loopholes are there to give the Administration the best chance at surviving a court challenge in some radical court, Judge shopped by the left. In this Episode of "Stinchfield" we go through the exact portions of the Executive Order Big Pharma is looking to exploit 24 hours after President Trump signed it. The Wellness Company prides itself on pushing back against censorship and tyranny. It's why it has developed a series of prescription drug medical emergency kits including a parasite cleanse that prescribed directly to you and delivered to your door to use incase of an emergency. BACK IN STOCK after 3x Sell-Outs! The Gold Standard in quality: the only product of its kind compounded by a 50-state licensed US pharmacy. Use promo code: GRANT to save 10% at: (Click Link Below) https://www.twc.health/products/ivermectin-mebendazole?ref=GRANT Also the prescription medical kits will allow you will have on hand m See omnystudio.com/listener for privacy information.

Hello nerds,After a steady stream of YouTube shorts and weekend content, I finally hopped back on the Nerds for Humanity livestream, and what a storm of absurdity we had to break down. If you're a center-left policy wonk, what follows may not make you feel better about the future of this country, but it'll make you feel like you're not going crazy for being outraged.We covered three stories. Each was a peek through the cracked window of American democracy, filtered through the bizarre prism of the Trumpist revival. From the Qatari jet that smells like a bribe, to a trade "deal" that undoes Trump's own blunder, to a shockingly good policy idea on pharma that no one—including the New York Times—bothered to cover. Let me walk you through each.Story 1: The $400 Million Jet From QatarImagine the headlines if President Biden accepted a half-billion-dollar luxury jet from the Saudi royal family to use as Air Force One. Now imagine if that jet was offered as a "gift" from a foreign government with ties to Hamas, with the only assurance being that it would later be displayed at the Trump Presidential Library. Sound plausible? That's what's on offer from Qatar to Donald Trump."You're going to disobey the order of the Supreme Court, deport people without due process, and accept a $400 million plane from a foreign government? That hurts your brain." — Me, in stunned disbeliefTrump defenders say it's a harmless donation. But even MAGA forums seemed uneasy. Fox News barely covered the story, and when they did, they quickly buried it. The idea that the future Air Force One—a flying command center during national crises—could be a foreign-made gift? That's not just sus. It's a Trojan Horse with wings."Didn't the Trojans give a gift, too?" — My live commentaryThe irony? This is the same base that cries foul about Hunter Biden's art sales and corruption. Yet when Trump auctions face-time dinners via a crypto coin and deregulates crypto enforcement, it's apparently savvy business. When he accepts a potentially compromised aircraft from a regime that also hosts Taliban leaders, it's not treason—it's branding.Story 2: The Uncelebrated Win on Drug PricingCredit where it's due. In a rare moment of policy lucidity, Trump proposed a Most Favored Nation (MFN) pricing strategy for pharmaceuticals. The idea? The U.S. shouldn't pay more than other countries for the same drug. If this actually gets done—really done, not just tweeted and forgotten—it would be a substantive victory for Americans crushed by high drug costs."Obama talked about it, Biden tried Medicare negotiation, but Trump just said: screw it, we're not paying more than Canada or the U.K."Surprisingly, no one wanted to talk about it. Not Fox. Not the New York Times. The former, presumably because Trump's win wasn't culture war red meat. The latter? Maybe it doesn't fit the preferred narrative."Poopy stinky. Freaking New York Times had Belichick's girlfriend on the homepage before the pharma deal."When both major media outlets fail to cover a story that affects the lives of tens of millions of Americans, it's not just media bias—it's systemic rot. We'd rather scream about TikTok bans and border clashes than do the hard work of evaluating policy.Story 3: The China Deal That Wasn'tTrump declared a "historic trade win" with China. The truth? He rolled back tariffs he imposed just a month prior. The markets cheered, but not because of a deal—because Trump stopped hurting them. There was no grand negotiation, no concession from China, just a chaotic game of poker where Trump folded and called it a win."This is your guy? The art of the deal? It's like he declared mango Gatorade the best flavor and MAGA was like ‘Oh yeah I've always loved mango.'"What's worse is the White House crowed about this as if it were the new Marshall Plan. It wasn't. It was a Ctrl-Z of his own failed policy."The only people who thought this was a win were Trump and the Fox chyron writers."The Real TakeawayLet me be painfully honest: we're living in an era of selective outrage and performative governance. One side celebrates crimes if it's their guy. The other side buries policy wins if it contradicts their narrative. Both parties play to their base, and media outlets amplify the rage bait because nuance doesn't generate clicks."Flooding the zone isn't just a Bannon tactic. It's a way to make Americans so overwhelmed they stop caring."We should care. Because accepting a luxury plane from a foreign adversary is not normal. Because a policy that could reduce your grandma's insulin cost should be front-page news. And because calling a self-inflicted trade mess a triumph is gaslighting the electorate.Final ThoughtsThree takeaways, nerds:* Yes to the Pharma Deal. If Trump can actually execute on MFN pricing and codify it into law, that would help millions. I'll cheer it. Just don't let it be another Trumpcare or wall that never gets built.* Hell no to the Qatar Jet. That's not a donation. It's a golden leash from a foreign monarchy with interests diametrically opposed to ours. The idea that it could be used as Air Force One is reckless.* Wake up to the media failures. When both Fox and the Times fail in opposite ways, we lose. We have to stop outsourcing our discernment to headline editors.If you got this far, thank you. If you want to support the channel and help offset the cost of livestream software, thumbnail generators, and custom music, consider becoming a YouTube channel member. You'll get a shout-out on every stream and help keep the nerd train rolling.Bye nerds. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit nerdsforhumanity.substack.com

Goods qualifying under the Nairobi Protocol (subheadings 9817.00.92-96) are exempt from MFN duties, but also from Section 301 and IEEPA duties.  Here, we provide a high-level review of the qualification requirements.

In this episode, Neal Bloom chats with Misti Cain, the new Managing Director of Techstars San Diego powered by SDSU. They discuss the upcoming Year 3 of the program, the application process, and what makes an ideal founder and company for the accelerator. Misty shares insights into the benefits of the SDSU partnership, the updated investment terms, and the importance of community and mentorship in the Techstars ecosystem.Key Topics:- Introduction of Misti Cain as the new Managing Director- Overview of Techstars San Diego powered by SDSU Year 3- Application details: Open from April 8 to June 11, 2024- Ideal founder and company profile- Benefits of the SDSU partnership- Updated investment terms: $220,000 total with $200,000 uncapped MFN safe- Importance of community and mentorship- Shoutout to Ryan Kuder for his contributions to Techstars in San Diego- Misty's favorite taco spot: PuestoLinks and Resources:- Techstars San Diego powered by SDSU Information- Refer FoundersConnect with Misti Cain:- LinkedIn: Misti Cain https://www.linkedin.com/in/misticain/Connect with Neal Bloom:- LinkedIn: Neal Bloom https://www.linkedin.com/in/nealbbloom- Twitter: @NealBloom https://twitter.com/NealBloom This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit risingtidepartners.substack.com/subscribe

Applications are open for the next accelerator program! In this episode, Neal Bloom chats with Misti Cain, the new Managing Director of Techstars San Diego powered by SDSU. They discuss the upcoming Year 3 of the program, the application process, and what makes an ideal founder and company for the accelerator. Misty shares insights into the benefits of the SDSU partnership, the updated investment terms, and the importance of community and mentorship in the Techstars ecosystem. Key Topics: - Introduction of Misty Cain as the new Managing Director - Overview of Techstars San Diego powered by SDSU Year 3 - Application details: Open from April 8 to June 11, 2024 - Ideal founder and company profile - Benefits of the SDSU partnership - Updated investment terms: $220,000 total with $200,000 uncapped MFN safe - Importance of community and mentorship - Shoutout to Ryan Kuder for his contributions to Techstars in San Diego - Misty's favorite taco spot: Puesto in Del Mar   Links and Resources: - Techstars San Diego powered by SDSU Information - Refer Founders   Connect with Misty Cain: - LinkedIn: Misti Cain https://www.linkedin.com/in/misticain/ Connect with Neal Bloom: - LinkedIn: Neal Bloom https://www.linkedin.com/in/nealbbloom - Twitter: @NealBloom https://twitter.com/NealBloom